DrGaP: A Powerful Tool for Identifying Driver Genes and Pathways in Cancer Sequencing Studies  by Hua, Xing et al.
ARTICLE
DrGaP: A Powerful Tool for Identifying Driver Genes
and Pathways in Cancer Sequencing Studies
Xing Hua,1,2 Haiming Xu,1,3 Yaning Yang,2 Jun Zhu,3 Pengyuan Liu,1,* and Yan Lu1,*
Cancers are caused by the accumulation of genomic alterations. Driver mutations are required for the cancer phenotype, whereas pas-
senger mutations are irrelevant to tumor development and accumulate through DNA replication. A major challenge facing the field of
cancer genome sequencing is to identify cancer-associated genes with mutations that drive the cancer phenotype. Here, we describe a
powerful and flexible statistical framework for identifying driver genes and driver signaling pathways in cancer genome-sequencing
studies. Biological knowledge of the mutational process in tumors is fully integrated into our statistical models and includes such vari-
ables as the length of protein-coding regions, transcript isoforms, variation inmutation types, differences in backgroundmutation rates,
the redundancy of genetic code, and multiple mutations in one gene. This framework provides several significant features that are not
addressed or naively obtained by previous methods. In particular, on the observation of low prevalence of somatic mutations in indi-
vidual tumors, we propose a heuristic strategy to estimate the mixture proportion of chi-square distribution of likelihood ratio test
(LRT) statistics. This provides significantly increased statistical power compared to regular LRT. Through a combination of simulation
and analysis of TCGA cancer sequencing study data, we demonstrate high accuracy and sensitivity in our methods. Our statistical
methods and several auxiliary bioinformatics tools have been incorporated into a computational tool, DrGaP. The newly developed
tool is immediately applicable to cancer genome-sequencing studies and will lead to a more complete identification of altered driver
genes and driver signaling pathways in cancer.Introduction
All cancers arise as a result of changes that have occurred in
the DNA sequence of the genome of cancer cells.1 Next-
generation sequencing (NGS) technologies have revolu-
tionized cancer genomics research by providing an
unbiased and comprehensive method of detecting somatic
cancer genome alterations, including nucleotide substitu-
tions, small insertions and deletions, copy-number alter-
ations, and chromosomal rearrangements.2 Recent
sequencing experiments have brought success in the iden-
tification of several cancer-associated genes that were
frequently mutated in tumors, including IDH1 (MIM
147700) and IDH2 (MIM 147650) in gliomas,3 DNMT3A
(MIM 602769) in acute myeloid leukemia,4,5 BAP1 (MIM
603089) in metastasizing uveal melanomas6 and malig-
nant pleural mesothelioma (MESOM [MIM 156240]),7
ARID1A (MIM 603024) in ovarian clear cell carcinoma8
and gastric cancer,9 PHF6 (MIM 300414) in T cell acute
lymphoblastic leukemia,10 MEN1 (MIM 613733) and
DAXX (MIM 603186)/ATRX (MIM 300032) in pancreatic
neuroendocrine tumors,11 ARID2 (MIM 609539) in hepa-
tocellular carcinoma,12 MLL2 in diffuse large B cell lym-
phoma,13 GRIN2A (MIM 138253)14 and GRM3 (MIM
601115)15 in melanoma, and PBRM1 (MIM 606083) in
renal carcinoma.16 As genomic sequencing experiments
continue to identify large numbers of novel cancer muta-
tions, one big challenge for cancer biologists that remains
is to distinguish driver mutations from the larger number
of passenger mutations. An impetus for the better identifi-1Department of Physiology and the Cancer Center, Medical College of Wiscons
versity of Science and Technology of China, Hefei, Anhui 230026, China; 3Ins
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The Americancation of driver mutations is the potential therapies
targeted against the products of these aberrant genomic
alterations.1,2
Driver mutations are required for the cancer phenotype,
whereas passenger mutations are irrelevant to tumor devel-
opment and accumulate through DNA replication. In gen-
eral, identification of driver genes involves statistical tests
of mutated genes followed by experimental validation.
The latter involves tailored in vitro and in vivo experi-
ments that collectively form a powerful approach to
validate driver genes. However, large-scale functional vali-
dation is time consuming and cost prohibitive. Further-
more, such validations are limited because there are no
universal functional assays that are suitable for assessing
all types of genes and pathways that can be altered in
cancers.2 From a statistical point of view, driver genes are
defined as those for which the nonsilent mutation rate is
significantly higher than a background (or passenger)
mutation rate. Silent mutations do not change amino
acid residue and generally do not affect protein function
and activity and are therefore considered to be passenger
mutations. Statistical methods and computational tools
are now actively being developed to attempt to assess func-
tional significance of a mutated gene in cancer sequencing
studies.17–24 However, applying biological knowledge of
the mutational process in tumors into statistical models
is not trivial and has not been adequately tested. These bio-
logical considerations include length of protein-coding
regions (CDS), variation in transcript isoforms, variation
in mutation types, differences in background mutationin, Milwaukee, WI 53226, USA; 2Department of Statistics and Finance, Uni-
titute of Bioinformatics, Zhejiang University, Hangzhou, Zhejiang 310029,
y of Human Genetics. All rights reserved.
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Figure 1. Overview of DrGaP Analysis Pipeline
The core of the pipeline includes input of tumor mutation data, sequencing analysis of somatic mutations, tabulation of somatic var-
iants, significance test of driver genes and pathways, and summary and output of results. Dashed lines indicate optional steps.rates, redundancy of genetic code, and number of muta-
tions in one gene. These factors have not yet been fully
addressed by current methods in the quest of identifying
driver genes.
There is now abundant evidence that alteration of driver
genes can be productively organized according to the
biochemical pathways and biological processes through
which they act.25 Driver mutations can be either common
or rare and identification of rare driver mutationsmay pose
a potential challenge. It is possible that mutation in one
member of a collection of functionally related genes may
result in the same net effect. Furthermore, mutations in
certain genes may be observed less frequently if they play
functional roles in later stages of tumor development,
such as metastasis. As a result, these drivers will appear to
be sparsely distributed across a larger number of genes
than we expect. Large sample sizes are required to detect
these infrequently mutated cancer-associated genes. Alter-
natively, by analyzing these drivers at the pathway level,
the frequency of rare mutations is accumulated and can
be detected with sufficient power. Thus, there is an
increasing interest in the identification of driver pathways
in tumor formation and progression.26
To meet these challenges, we developed a powerful
computational tool, DrGaP (driver genes and pathways),
for use in cancer genome-sequencing studies (Figure 1).
DrGaP incorporates our statistical approaches and several
auxiliary bioinformatics tools for better driver gene identi-
fication. Biological knowledge of the mutational process is
fully integrated into the statistical models and provides
several significant improvements and increased power
over current methods.Material and Methods
Lessons from Recent Large-Scale Cancer Sequencing
Studies
To more accurately model the mutational process in our methods,
we first described several significant features learned from recent440 The American Journal of Human Genetics 93, 439–451, Septemblarge-scale cancer genome-sequencing data generated from
The Cancer Genome Atlas (TCGA). Specifically, whole-exome
sequencing data of 119 lung adenocarcinoma (LUAD) and 127
lung squamous cell carcinoma (LUSC) tumor samples were
analyzed. We observed that a total of 7,755 and 11,125 genes
were mutated at protein-coding regions (CDS) in LUAD and
LUSC, respectively. However, the numbers of somatic mutations
vary significantly between tumor histologies and also between in-
dividual tumors (Figure S1 available online). The number of silent
mutations, which are used for estimating background mutation
rates, ranges from zero to several hundred per individual tumor.
LUSC was observed to have higher background mutation rates
than LUAD, suggesting the necessity of estimating individual
background mutation rates in statistical models.
The mutation rate depends not only on the mutated nucleotide
base but also on the neighboring sequences. For example, somatic
variants occur predominantly at G/C base pairs with the most
prevalent changes being G/C to A/T and G/C to T/A in tobacco
exposure-related tumors17,27,28 (Figure S2). Furthermore, muta-
tions at G/C show differential rates between CpG and non-CpG
sites because of deamination of cytosine at CpG dinucleotides.29
To reduce the risk of bias, 11 different mutation types are consid-
ered in our statistical models (Table S1).
We also commonly observed that some tumors do not have any
silent mutations in specific mutation types (Figure S3), which can
lead to a problem in estimating background mutations. Therefore,
Bayesian methods are favored to estimate the distribution of
background mutation rates in individual tumors.30 Based on the
analysis of silent mutations from large-scale TCGA cancer
sequencing data, we found that a prior beta distribution Bða; bÞ
of background mutation fits the real data better than the
uniform distribution that has been commonly used in previous
studies17,18,22–24 (Figure S4).
Because of the nature of NGS, some CDS cannot be captured in
library preparation or by sequencing because of the existence of
regions with high GC content. Somatic mutations are called
only when both tumor andmatched normal tissue simultaneously
have sufficient sequence coverage that is generally defined to be at
least 83 for identifying mutations in whole-exome studies.31 We
estimated that, on average, less than 85% of CDS in the genome
have sequence coverageR83 in both tumor and matched normal
samples by analyzing TCGA lung cancer sequencing data (Fig-
ure S5A and Tables S2 and S3). Furthermore, the proportion ofer 5, 2013
Table 1. Biological Information Is Integrated into Statistical
Models
Biological Knowledge Statistical Interpretation
transcript isoforms sum aggregate of CDS from multiple
isoforms of the same gene
variation in mutation types consider 11 different mutation types
background mutation rates beta prior of hij which is background
rate of mutation type j in individual i
differences in background
mutation rates
estimate separate mutation rates hij
for each individual tumor
redundancy of the genetic code define Njk and Mjk as the number of
base pairs in CDS of gene k that can
give rise to nonsilent and silent
mutations
multiple mutations in one gene addressed by the Poisson process
sequencing coverage cik is the proportion of CDS with a
minimum eight sequence coverage in
both a tumor and its matched normal
DNA from individual i
CDS size
P
jðNjk þMjkÞ ¼ 3L where L is length
of CDS for gene kCDS with sufficient coverage varies substantially among genes
within the same sample (Figure S5B). Statisticalmodels accounting
for sequence coverage may increase sensitivity of identifying
driver mutations. Below, we will describe how biological informa-
tion is integrated into our statistical models (Table 1).
Poisson Process
To better identify driver mutations, we introduced a Poisson
process to model the random nature of somatic mutations.
Suppose we have I tumor samples to analyze and J types of
mutations (Table S1) across the tumor samples. For each sample,
K genes are analyzed. For each type j we will calculate the
number of base pairs in CDS of gene k that can give rise to
nonsilent and silent mutations. These counts are denoted by
Njk and Mjk, respectively. Furthermore, suppose that for sample
i, the number of nonsilent and silent mutations in the screened
CDS of type j is a Poisson process with rate rijk and hij, respec-
tively, where rijk ¼ hij þ ajk, hij is the background mutation rate
in type j from sample i, and ajk is the driver effect and can be
interpreted as the increased rate of mutation due to the extent
of the ‘‘driver’’ property of gene k of type j. Suppose that nijk
and mijk are the number of nonsilent and silent mutations
actually observed in gene k with type j from sample i. The prob-
ability of observing a given set of mutations of type j in gene k
from sample i follows the Poisson distribution for nonsilent
and silent mutations:
Pr

nijk; rijk
 ¼ eNjkðhijþajkÞ hij þ ajknijkN
nijk
jk
nijk!
(Equation 1)
Pr

mijk; hij
 ¼ eMjkhijhmijkij M
mijk
jk
mijk!
: (Equation 2)
Both Njk and Mjk can be potentially further adjusted by the
sequence coverage of CDS, cik to increase sensitivity of identifying
driver mutations, where cik is defined as the proportion of CDS
with sufficient sequence coverage in both a tumor and its matchedThe Americannormal DNA at gene k in individual i (Figure S5). The nonsilent
mutations can be further classified into five different functional
types, i.e., missense, splicing, nonsense, in-frame, and out-of-
frame indel.
Log-Likelihood
For nonsilent mutations, the log-likelihood of observed nonsilent
mutations can be expressed
Lnonsilent

nijk;rijk
 ¼ log Y
i
Y
j
Y
k
Pr

nijk;rijk

¼
X
i
X
j
X
k
log Pr

nijk;rijk

¼
X
i
X
j
X
k
Njkhij þ ajk
þ nijk log

Njk

hij þ ajk
 lognijk!:
(Equation 3)
For silent mutations, the log-likelihood is
Lsilent

mijk;hij
 ¼ log Y
i
Y
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k
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i
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j
X
k
log Pr

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
¼
X
i
X
j
X
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Mjkhij þmijk logMjkhij
 logmijk!:
(Equation 4)
Maximum Likelihood Estimation
We can obtain the maximum likelihood estimation (MLE) of hij
from Equation 4:
h^ij ¼
P
k
mijkP
k
Mjk
: (Equation 5)
Note that in real data, some h^ij can be 0 if the sample i has no
mutations of type j (Figure S3). Therefore, Bayesian methods will
be used to estimate the distribution of hij in individual tumors,
which borrow information from all the samples for estimating
each individual hij and therefore give more smooth estimates.
30
Based on the observation from the large-scale TCGA data, a prior
beta distribution Bða; bÞ of hij will be used, which is more appro-
priate than the uniform distribution that has been commonly
used in previous studies17,18,22–24 (Figure S4). Because it is the con-
jugate prior of the binomial distribution, the posterior distribution
is still a beta distribution. We can estimate h^
ðpriorÞ
ij ¼ a^=ða^þ b^Þ and
h^
ðpostÞ
ij ¼ ða^þ
P
kmijkÞ=ða^þ b^þ
P
kMjkÞ. a^ ¼ xðxð1 xÞ=v  1Þ and
b^ ¼ ð1 xÞðxð1 xÞ=v  1Þ are the moment estimation of the
parameters a and b, where x ¼ 1=IPih^ij is the sample mean and
v ¼ 1=IPiðh^ij  xÞ2 is the sample variance. Then, we can obtain
the MLE of ajk by substituting h^ij into Equation 3, which is the
root of the following equation:
NjkI þ
X
i
nijk
h^ij þ a^jk
¼ 0: (Equation 6)Journal of Human Genetics 93, 439–451, September 5, 2013 441
It is subject to the constraint ajkR0. If the root of Equation 6 is
negative or nijk ¼ 0; for all i, then a^jk will be 0.Likelihood Ratio Test
Significance of the driver mutation rate ajk for type j in gene k can
be tested by the likelihood ratio test (LRT) under null hypothesis.
If we want to test each single mutation type of ajk separately, it will
be a one-side test and the parameter space of ajk is ½0;NÞ. LRT will
be performed under H0: ajk ¼ 0:
LRTjk ¼ 2
X
i
 
Njka^jk þ nijk log
h^ij þ a^jk
h^ij
!
 1
2
c20 þ
1
2
c21:
(Equation 7)
However, based on our empirical observation (Figures S1 and S3),
some hij may be too small to observe any mutations in samples.
This results in a larger probability of zero estimation of ajk than ex-
pected under the above Poisson models and may lead to incorrect
type I error. To remedy this problem, we will correct the mixture
proportion of asymptotic distribution by a factor ε:
LRTjk 

1
2
þ ε

c20 þ

1
2
 ε

c21: (Equation 8)
We may estimate the parameter ε by using simulations ε^ ¼
0:5#fðk; jÞ :LRTjk > 0g=JK (Appendix A). Similarly, if we want
to test whether any mutation type has increased rate of mutation
resulting from the extent of the ‘‘driver’’ property of gene k, the
distribution of the statistic of LRT will be a more complicated
mixture of chi-square distributions. The null hypothesis H0
is a1k ¼/ ¼ aJk ¼ 0; the alternative hypothesis H1 is ajk > 0
for some j. We can express the statistic of LRT in gene k as
LRTk ¼
XJ
j¼1
LRTjk 
XJ
d

J
d

1
2
þ ε
Jd
1
2
 ε
d
c2d :
(Equation 9)
Throughout the manuscript we will use the term LRT-S when
multiple types of mutations are summed into a single type in the
likelihood ratio tests (i.e., J ¼ 1 and ε ¼ 0 in Equation 9); LRT-M
when multiple types of mutations are jointly considered in likeli-
hood ratio tests but without correction of the mixture proportion
of chi-square distribution (i.e., J > 1 and ε ¼ 0); and LRT-C when
multiple types of mutations are jointly considered in likelihood
ratio tests with correction of the mixture proportion of chi-square
distribution by estimating ε (i.e., J > 1 and ε > 0). LRT-S, LRT-M,
and LRT-C represent three different likelihood ratio test statistics
and their asymptotic distributions are a mixture of chi-square dis-
tribution. These statistics may have different statistical power for
identify driver genes. The Benjamini-Hochberg method will be
used to control false discovery rate (FDR) in all statistical tests.32Pathway Approach
The above Poisson models (Equations 1 and 2) for a single gene
can be easily extended to analyze a pathway or gene set by treating
multiple genes within a pathway as a ‘‘big’’ gene. In brief, somatic
mutations within a pathway are counted and classified into silent,
missense, nonsense, splicing mutations, in-frame, and out-of-
frame indels; each type of mutation except indels are further
classified into one of nine nucleotide types based on the base of in-
terest and its flanking bases and location of CpG islands (Table S1).442 The American Journal of Human Genetics 93, 439–451, SeptembSimilarly, the expectations of base pairs that can give rise to
different types of mutations are summed: Nijp ¼
P
kcikNijpk and
Mijp ¼
P
kcikMijpk where gene k belongs to pathway p and cik is
the proportion of CDS with at least 83 in both a tumor and its
matched normal DNA. LRT will be performed to examine the sig-
nificance of a pathway. Currently, we have collected 880 gene sets,
including 186 KEGG, 217 BioCarta, and 400 Reactome pathways
and multiple user-specified gene sets such as Chromatin remodel-
ing, HMTs histone methylation reader, HATs HDACs, and DNMTs
and Methyl-CpG binding.
Simulation
We evaluated our DrGaP statistical approaches through simula-
tions under a range of scenarios comparable to recent tumor
mutation data generated by the TCGA sequencing projects. Two
different strategies of simulations were performed. One is to
generate somatic mutations from probability models. In brief,
backgroundmutation rate hwas first sampled from a beta distribu-
tion, i.e., h  Bð1;10000Þ, which we observed in TCGA data sets
(Figure S4). Then, we generated silent mutations by Poisson dis-
tribution with parameter l ¼ Mh where M is sampled from
Nð10000;2000Þ and is the number of base pairs that can give
rise to silent mutations and h is the background mutation rate.
Driver nonsilent mutations were generated in a similar way (i.e.,
a  Bð1;10000Þ). To evaluate the effects of multiple types of muta-
tions on statistical power, we considered that there are 1, 5, and 11
types of driver mutations occurring in tumor samples. In each
simulation, we generated 100 tumor samples with 10,000 genes
and 11 different mutation types. Each simulation was replicated
100 times; the power is defined as the proportion of driver genes
identified by a statistical test with a significance level of 0.05.
Another simulation strategy is to generate mutation data by
directly sampling somatic mutations in TCGA data sets, including
LUAD, LUSC,33 high-grade serous ovarian cancer (HGS-OvCa),34
and colorectal carcinoma (CRC)35 (Table S4). In each data set, we
randomly assigned observed somaticmutations intoCDS and their
splicing sites (within 2 bp of an exon/intron boundary) across the
genome. To maximally match simulated data to real observed
mutation data, themutation types (Table S1) remained unchanged
during sampling. For example, if an observed somatic mutation in
CDS is A/G, we randomly sample a base position corresponding
to base A in CDS across the genome and change A to G at that
position. Then, we determine whether the new mutation A/G is
a silent or nonsilent mutation according to the genetic code. We
applied the same sampling rule to mutations occurring in CpG
sites. After themutation reshuffling, themutations become evenly
distributed across the genome. Finally, we chose 100 simulated
tumor samples from each data set and made 300 driver genes by
adding 2–5 nonsilent mutations to these 300 selected genes.
With these simulation data, we also compared our DrGaP with
several previous methods, including Bernoulli,24 Binomial-S and
Binomial-M,17,18,22,23 Poisson,19 and TRAB.21 In order to test driver
mutations, these statistical models need to specify background
mutation rates. However, estimation of backgroundmutation rates
is not explicitly described inmost of thesemethods. For a fair com-
parison, we used the same method as our DrGaP to estimate indi-
vidual background mutation rates, hij, for the Bernoulli
method.24 Averaging h^ij over individual tumors, we obtained back-
ground mutation rates of different mutation types ðh^jÞ that were
subsequently used for multiple-parameter Binomial model (Bino-
mial-M)17,18,22,23 and Greenman’s Poisson model.19 Similarly, we
estimated the overall background mutation rate h^ ¼ 1=IJPiPjhijer 5, 2013
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Figure 2. Parameter Estimation and
Type I Error in DrGaP
(A and B) Parameter estimation of h and a.
(C–E) Distribution of p values from dif-
ferent likelihood ratio statistics: LRT-M,
LRT-C, and LRT-S.
(F) Q-Q plot of uniform distribution [0, 1]
and p values from LRT-C under null
hypothesis.
LRT-M refers to LRT test jointly consid-
ering multiple types of mutation without
estimating ε; LRT-C refers to LRT test
jointly consideringmultiple types ofmuta-
tions and correctingmixture proportion of
chi-square distribution by estimating ε.
LRT-S refers to LRT test considering a single
type of mutation. That is, multiple types of
mutations are summed into a single type
in LRT-S.in the sample and used it for single-parameter Binomial model
(Binomial-S).17,18,22,23 The TRAB method is a Bayesian method
that models the occurrence of tumor mutation as the Poisson-
Gammadistribution.21We implemented its R codewith thedefault
parameter setting in our simulations.Software
Several bioinformatics tools, together with the newly proposed
statistical approaches, are integrated into an open-source software
called DrGaP (Figure 1). Other auxiliary bioinformatics tools were
also developed including (1) estimating depth of coverage of CDS
in paired samples from sequence alignment files (i.e., BAM), (2)
determining the sum aggregate of CDS from multiple isoforms,
(3) analyzing sequences in CDS, and (4) mutation tabulation.Results
Simulation Studies
We first evaluated type I error and parameter estimation
under the null hypothesis ðajk ¼ 0Þ. Estimators of a and hThe American Journal of Human Genare unbiased under the null hypothe-
sis. p values from statistical tests
that either consider a single type
of mutation (i.e., LRT-S) or jointly
consider multiple type of mutation
without correcting LRT statistics
(i.e., LRT-M) are not uniformly
distributed [0, 1]. The LRT-M test is
also conservative. We thus proposed
to estimate the mixture proportion
of chi-square distribution, ε. The
corrected LRT (i.e., LRT-C) has uni-
formly distributed p values and
approximately correct type I error
under the null hypothesis (Figure 2).
When at least one of the mutation
types has an increased rate of occur-
rence in tumor samples (i.e., under
the alternative hypothesis), estima-tors of a and h are also unbiased (Figure S6). As expected,
the statistical power for detecting mutations increases
when the mutations rate a increases. LRT-C performs
consistently better than the other two likelihood ratio sta-
tistics, LRT-S and LRT-M, in all of scenarios. The increased
power of LRT-C over LRT-M becomes more apparent when
there are multiple types of driver mutations that occur in
tumor samples (Figure 3). The performance of LRT-S is
improved when multiple types of driver mutations occur
in tumor samples. This is because as increased types of
mutations occur, the bias in estimating mutation rates is
reduced when treating all mutations as a single type in
LRT-S. We observed that lower background mutation often
leads to a larger estimate of ε and thus has a higher impact
on likelihood ratio statistics (Figure 4). Under these circum-
stances, statistical tests correcting the mixture proportion
of chi-square distribution (i.e., LRT-C) show a greater
advantage over those without correction (e.g., LRT-M).
We will present results only from LRT-C for our methods
below.etics 93, 439–451, September 5, 2013 443
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Figure 3. Statistical Power of Three Statistics in DrGaP
(A) Only one type of driver mutation occurred in tumors.
(B) Five of 11 types of driver mutations occurred in tumors.
(C) All 11 types of driver mutations occurred in tumors.
For comparison, the total driver mutation rates are equal among
the three scenarios; the mutation rates of individual types are
also equal in the latter two scenarios.
Figure 4. Impact of Background Mutation Rate on Likelihood
Ratio Statistics
Lower background mutation (h) often leads to a larger estimate of
the mixture proportion of chi-square distribution (ε).
444 The American Journal of Human Genetics 93, 439–451, SeptembWe then compared our DrGaP approach with several
previous methods that use either Bernoulli,24 Bino-
mial,17,18,22,23 Poisson,19 or Poisson-Gamma21 related
statistical models to detect driver mutations. TRAB is a
Bayesian approach and computes a posteriori probability
of a driver mutation, whereas the other methods give a
p value, i.e., a probability that none of driver mutations
is true. We therefore used receiver operating characteristic
(ROC) curves to evaluate the sensitivity and specificity of
these statistical methods for detecting driver mutations.
First, we evaluated their performance under various
numbers of driver mutation types occurring in tumor
samples (Figure 5). Our method generally has higher sensi-
tivity and specificity than the other methods in different
scenarios. It shows a greater advantage over the other
methods when multiple types of driver mutations occur
in tumors. The performance of Bernoulli, Binomial-S,
and TRAB methods is comparable, whereas the perfor-
mance of Binomial-M depends on the number of mutation
types and often works better when fewer types of driver
mutation occur in tumors. Second, we evaluated their
performance in data simulated from TCGA cancer
sequencing studies (LUAD, LUSC, CRC, and HGS-OvCa)
that show a wide spectrum of somatic mutations in
tumors (Figure S7). Similarly, DrGaP consistently outper-
forms the other methods in four different TCGA data
sets. It works relatively better in LUAD and LUSC than in
nonhypermutated CRC and HGS-OvCa data sets. Tumors
in LUAD and LUSC often have higher frequencies of
somatic mutations and a large variability in background
mutation rates.
Althoughmultiplemethods exist to detect a single driver
gene, few methods to detect a whole driver pathway are
available. Our method is flexible and is also applicableer 5, 2013
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Figure 5. ROC Plots of Sensitivity and Specificity of Six Statisti-
cal Methods under Different Tumor Mutation Patterns
(A) Only one type of driver mutation occurred in tumors.
(B) Five of 11 types of driver mutations occurred in tumors.
(C) All 11 types of driver mutations occurred in tumors.
The Americanfor identifying driver pathways and gene sets. We therefore
compared our method with PathScan for identifying driver
pathways. PathScan is a tool for testing whether a pathway
is significantly mutated in tumors. It is based on a Ber-
noulli distribution and its statistic is the number of genes
that are mutated in the pathway.37 Simulation studies
shows that DrGaP also has increased power over PathScan.
The advantage of DrGaP over PathScan is more evident
when fewer driver genes are mutated in the pathway
(Figure S8).
Comparison of the Results from the Study of Ding
et al.17
We applied our DrGaP methods to several cancer
sequencing studies (Table S4). As before, in each study,
somatic mutations are classified into silent, missense,
nonsense, splicing mutations, in-frame, and out-of-frame
indels. Each type of mutation, except indels, is further
classified into nine nucleotide types based on the base of
interest and its flanking bases and location of CpG islands
(Table S1). These mutation data were then input into our
DrGaP analysis pipeline (Figure 1) for identifying driver
genes and pathways.
Ding et al.17 sequenced coding exons and splice donor/
acceptor sites (dinucleotides in the 50/30 ends of introns)
of 623 genes in 188 LUAD samples and identified 1,013
nonsilent mutations. They also selected a subset of 250
genes to identify 108 silent mutations for measuring a
background mutation rate. Ding et al.17 identified 22
driver genes with 5% FDR. Recently, Youn and Simon
also applied their approach to the same data set and
identified 28 genes with 5% FDR.24 A total of 20 genes
overlapped between Ding’s and Youn’s methods, and
together they identified 30mutated driver genes. However,
our DrGaP method identified 59 driver genes at 5% FDR
and identified 29 out of the 30 total genes by Ding and/
or Youn’s methods17,24 (Figure 6). The single gene that
was missed by our method reached marginal significance
(FDR ¼ 6%) and was the least significant in the combined
Ding and Youn list (Table S5).
In addition to its high reproducibility, DrGaP identified
an additional 30 driver genes: INSRR (MIM 147671),
DOCK3 (MIM 603123), PAK4 (MIM 605451), PIK3C3
(MIM 602609), FLT4 (MIM 136352), PAK7 (MIM
608038), LMTK2 (MIM 610989), TEC (MIM 600583),
PRKCG (MIM 176980), CDC42BPA (MIM 603412),
SLC38A3 (MIM 604437), JAK2 (MIM 147796), BAP1,
PIK3CG (MIM 601232), ROR2 (MIM 602337), MSH6
(MIM 600678), ERAS (MIM 300437), ROBO1 (MIM
602430), MKNK2 (MIM 605069), CDK17 (MIM 603440),
ACVR1B (MIM 601300), LMTK3, MKNK1 (MIM 606724),
RET (MIM 164761), SMAD4 (MIM 600993), IRAK2 (MIM
603304), GNAS (MIM 139320), TP63 (MIM 603273), FOS
(MIM 164810), and GATA1 (MIM 305371). Most have
been suggested to play important roles in tumorigenesis
in a broad range of published studies. For example, genetic
variation in TP63 was recently found to contribute to theJournal of Human Genetics 93, 439–451, September 5, 2013 445
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Figure 6. Driver Mutated Genes in the
Study Ding et al.17
Tumor samples with or without mutations
in genes are labeled green or red, respec-
tively. The red/blue/yellow banner across
the left side of the map shows the differ-
ence between genes selected by DrGaP
and those selected by the other methods
(Ding et al.17 and Youn and Simon24).
The genes covered by the red bar are iden-
tified by the Ding/Youn methods but are
missed by DrGaP and those covered by
the yellow bar are the additional genes
found by DrGaP. The genes covered by
the blue bar are those which both DrGaP
and Ding/Youn’s methods find significant.susceptibility of lung adenocarcinoma in two large lung
cancer genome-wide association studies.38,39 RET (also
called ret proto-oncogene) is a receptor tyrosine kinase
that is one of the cell surface molecules that transduce
signals for cell growth and differentiation. Germline
gain-of-function mutations are known to predispose to
multiple endocrine neoplasia type 2 (MEN2), characterized
bymedullary thyroid cancer, pheochromocytoma, and hy-
perparathyroidism.40 More recently, a novel fusion gene
between KIF5B (MIM 602809) and RET, as generated by a
pericentric inversion in chromosome 10, was identified
in lung adenocarcinomas.41–44 Jak2 is a protein tyrosine
kinase involved in a specific subset of cytokine receptor
signaling pathways and has been implicated in a variety
of cancers including lung and ovary.45,46 We believe our
method provides higher accuracy and sensitivity than
other methods for detecting driver mutated genes.
DrGaP is applicable not only to identify driver genes but
also to identify driver pathway or any gene sets. To illus-
trate its utility, we applied DrGaP to the data of Ding
et al.17 to find significantly mutated KEGG pathways
(Table S6). In their original pathway analysis, Ding and
her colleagues used two statistical methods. One is a bino-
mial test that examines whether nonsilent mutation rates
are higher than background mutation rates in a pathway;
the other is a Fisher’s exact test that examines whether446 The American Journal of Human Genetics 93, 439–451, September 5, 2013the number of gene mutations occur-
ring in a pathway is proportionally
higher than in the rest of the genome.
Recently, Wendl et al.37 also applied
their PathScan to the same data
set to resolve the inconsistencies
between binomial and Fisher’s tests
from the study of Ding et al.17 DrGaP
yielded largely consistent results with
PathScan, but the p values from
DrGaP tend to be smaller than those
from PathScan. However, there are a
few exceptions including Jak-STAT
and TGF-b signaling pathways.
Fisher’s tests gave FDR values of0.0006 and 0.03 for these two pathways whereas binomial
tests did not reach significance. PathScan concluded
that none of these pathways are significant. DrGaP found
these inconclusive pathways to actually be significant.
Indeed, mutations in the JAKs are often found in
myeloproliferative disorders (MPDs) and leukemia, and
the constitutive phosphorylation of STATs is a common
occurrence in many hematological and solid tumors.47
Alterations in TGF-b signaling are linked to a variety of
human diseases, including cancer and inflammation.
Disruption of TGF-b homeostasis occurs in several human
cancers.48
Lung Adenocarcinoma and Squamous Cell Cancers
We also applied DrGaP to the analysis of whole-exome
sequencing data of 119 LUAD and 127 LUSC tumor sam-
ples from TCGA. We found that 7,755 and 11,125 genes
were mutated in CDS in LUAD and LUSC, respectively.
Each individual tumor carried a median of 105 and 181
nonsilent mutations in LUAD and LUSC, respectively
(Figure S1). Such large numbers of mutations per tumor
are also observed in other tobacco-exposure related
tumors (e.g., larynx, oral cavity, esophagus, and bladder
cancers).49–51 Thus, it is critically important to apply statis-
tical approaches to narrow down amuch smaller and more
relevant list for subsequent functional validation.
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Figure 7. Numbers of DriverMutated Genes per Tumor in TCGA
Data Sets
LUAD, LUSC, nonhypermutated CRC, and HGS-OvCa.
Genes with <5% FDR from DrGaP are presented in the above
studies.Our method identified 110 driver mutated genes in
LUAD tumor samples at 5% FDR, accounting for approxi-
mately 0.5% of genes in the genome. Each individual
LUAD tumor carries a median of 6 driver mutations. In
LUSC tumor samples, a total of 260 driver genes were iden-
tified with amedian of 16 driver genes per tumor (Figure 7).
A total of 36 genes are commonly mutated in both LUAD
and LUSC tumors, including CDH10 (MIM 604555),
CSMD3 (MIM 608399), GRM1 (MIM 604473), KEAP1
(MIM 606016), LRP1B (MIM 608766), NAV3 (MIM
611629), NF1 (MIM 613113), and TP53 (MIM 191170),
to name a few (Tables S7 and S8). In addition, we identified
multiple driver pathways significantly mutated in LUAD,
including focal adhesion, MAPK, tight junction, apoptosis,
and cell cycle pathways (Table S9). In LUSC, multiple
cellular pathways including TGF-b, Hedgehog, mTOR,
Jak-STAT, and Wnt signaling pathways were significantly
mutated in tumors (Table S10). Interestingly, chromatin re-
modeling and histone methylation pathways were signifi-
cantly mutated in both LUAD and LUSC tumors.
Colorectal Cancer
We further applied DrGaP to the driver gene analysis of
two additional TCGA data sets (CRC and HGS-OvCa)
with low prevalence of somatic mutations. In CRC, we
analyzed 194 nonhypermutated tumor samples with a
median of 58 nonsilent mutations per tumor.35 DrGaP
identified a total of 44 driver genes with 0.05 FDR (Table
S11). Each nonhypermutated CRC tumor carries a median
of 4 driver mutations (Figure 7). TCGA reported 17 signif-
icantly mutated genes defined by FDR less than 10%
and/or manual curation,35 15 of which were also identified
by DrGaP. Two genes missed by DrGaP are MLK4 (MIM
614793) and EDNRB (MIM 131244). The q value of EDNRB
exceeds 5% in the TCGA study; there are 6 missense and 3
silent mutations detected in EDNRB in nonhypermutated
CRC tumors. DrGaP found an additional 29 driver genes,
of which SMAD2 (MIM 601366), LRP1B (MIM 608766),
BRAF (MIM 164757), TNFRSF10C (MIM 603613), ARID1AThe American(MIM 603024), LIFR (MIM 151443), ERBB4 (MIM
600543), SLITRK1 (MIM 609678), ATM (MIM 607585),
TGIF1 (MIM 602630), and CASP14 (MIM 605848) are
particularly interesting candidates. For example, LIFR is a
key tumor suppressor andmediates the action of the leuke-
mia inhibitory factor. Its activation has been reported in
the CRC and many other cancers.52,53Ovarian Carcinoma
In HGS-OvCa, we analyzed 316 tumor samples with a
median of 40 nonsilent mutations per tumor.34 We identi-
fied a total of 29 driver genes with 0.05 FDR and a median
of 1 driver mutations per tumor (Table S12). TCGA re-
ported 9 significantly mutated genes, 7 of which were
also identified by DrGaP. Two genes that were not detected
by DrGaP are FAT3 (MIM 612483) and GABRA6 (MIM
137143). Although these two genes were claimed to be
significantly mutated genes, their likelihood ratio FDR
and convolution FDR were reported 0.09 and 0.02 for
FAT3 and 0.09 and 0.12 for GABRA6 in the TCGA study.
Our DrGaP yielded FDR of 0.09 for FAT3 and 0.11 for
GABRA6. In addition, DrGaP identified an additional 22
driver genes in HGS-OvCa, of which HIST1H1C (MIM
142710), CREBBP (MIM 600140), RB1CC1 (MIM 606837),
BAI3 (MIM 602684), DUSP19 (MIM 611437), GNAS
(MIM 139320), CDC27 (MIM 116946), and EFEMP1
(MIM 601548) are particularly interesting candidates. For
example, RB1 (MIM 614041) signaling is the most signifi-
cant pathways altered in HGS-OvCa. RB1CC1 is RB1-induc-
ible coiled-coil 1, which enhances the RB1 pathway
through transcriptional activation of RB1, CDKN1A (MIM
116899), and CDKN2A (MIM 600160).54Discussion
A major challenge facing the field of cancer genome
sequencing is to identify cancer-associated genes with
mutations that drive the cancer phenotype. In this paper,
we described a powerful and flexible statistical framework
for identifying driver genes and pathways in cancer
genome-sequencing data. Our methods provide several
novel features that were either naively obtained or were
unattainable by previous methodologies.
First, biological knowledge of the mutational process
in tumors is fully integrated into our statistical models
(Table 1). Second, multiple types of mutations are consid-
ered to reduce the risk of bias in estimating mutation rates
in our statistical methods (Table S1 and Figure S2). This in-
creases statistical power compared with a single-type muta-
tion test in which all types of mutations are summed into
one. Third, we incorporate themixture proportion ε of chi-
square distribution in our LRT statistics. We observed that
some tumor samples have a very low backgroundmutation
rate h (Figure S3), leading to one-side LRT statistic as zero
to be overrepresented in the standard mixture chi-square
distribution under null hypothesis. Thus, the appropriateJournal of Human Genetics 93, 439–451, September 5, 2013 447
mixture chi-square distribution of the LRT statistics is
ð1=2þ εÞc20 þ ð1=2 εÞc21;0 < ε < 1=2 under H0. Our simu-
lation shows that considering parameter ε in the LRT statis-
tic (i.e., LRT-C) corrects type I error and increases statistical
power. Interestingly, the parameter ε was estimated up to
0.4 in lung cancer sequencing studies, suggesting the large
impact of parameter ε on likelihood ratio statistics. We
expect that our method will be of greater advantage for
analyzing tumors with low prevalence of somatic muta-
tions, such as in cancers of the hematological system.
Fourth, more appropriate and informative Bayesian prior
of background mutation rates, hij, was used in our statisti-
cal methods (Figure S4). After analyzing large-scale TCGA
data, we found that a prior beta distribution of background
mutation rates fits the real data better than uniform distri-
bution commonly used in previous studies.17,18,22–24 Fifth,
sequence coverage at CDS varies across studies, individual
tumors, and genes in NGS experiments (Figure S5). In our
methods, CDS sizes are adjusted for sequence coverage in
order to increase sensitivity of identifying driver muta-
tions. Finally, although multiple methods exist to detect
a single driver gene, few methods exist to detect a whole
driver pathway. Our methods can do both, because they
are implemented in the same statistical framework.
Because of the innovative features described above, we
believe our proposed methodology increases power and
sensitivity for identifying driver genes and driver path-
ways, compared to current methods. It should be also
noted that cancers with copy-number alterations may
cause allelic imbalance and thus potentially affect infer-
ence of somatic mutations. However, identification of
driver mutations in our methods is focused on observed
(or already detected) somatic mutations and its estimation
of mutation rate per se won’t be affected by copy-number
alterations.
All cancers are as a result of somatically acquired changes
in the DNA of cancer cells. However, how many driver
mutations does it take to make a tumor? Not all detected
somatic abnormalities present in a cancer genome are
required for the development of the cancer. Indeed, most
of them have made no contribution at all.1 On the basis
of age-incidence statistics, it has been suggested that com-
mon adult epithelial cancers such as breast, colorectal,
lung, and prostate require 5–7 rate-limiting events,
possibly equating to drivers, whereas cancers of the hema-
tological system may require fewer.55 We applied our tool
DrGaP to the analysis of four TCGA data sets: LUAD,
LUSC, nonhypermutated CRC, and HGS-OvCa. DrGaP
not only recaptured a large majority of driver genes previ-
ously reported by TCGA studies,33–35 but it also identified a
much longer list of additional candidate genes whose
mutations potentially drive cancer phenotypes. Most of
them have been suggested to play important roles in
neoplasm initiation and progression. Numbers of somati-
cally mutated driver genes vary among individual tumors
and cancer types. We observed a median of 6 driver muta-
tions in LUAD, 16 in LUSC, 4 in nonhypermutated CRC,448 The American Journal of Human Genetics 93, 439–451, Septemband 1 in HGS-OvCa (Figure 7). Interestingly, different
tumors usually carry different sets of driver mutations.
These data demonstrated the extreme complexity and het-
erogeneity of tumor cells and have important implications
in targeted cancer therapy.
Large number of driver mutations involved in lung
tumors, especially in LUSC, may be also attributed to
potent carcinogen from life-long tobacco exposure.
Tobacco exposure causes a large number of somatic muta-
tions on the genome. This increases the chance that muta-
tions conferring small cell growth advantage (i.e., small
effect) are selected in lung microenvironment. Many
mutations with small effects can be accumulated in a
specific group of cells over time and collectively lead to
tumor initiation and progression in lung. In tumors such
as HGS-OvCa with a low prevalence of somatic mutations,
fewer driver mutations (but with large effects) are expected
in each individual tumor.
In the past few decades, a number of agents have
been developed to target pathways that are deregulated
in cancer. However, even when there is a well-known
target and a highly specific drug, increased survival
is generally very limited.56 For example, Gefitinib, an
EGFR-tyrosine-kinase inhibitor, is a standard first-line
treatment for patients with advanced non-small-cell
lung cancer whose tumors have activating EGFR (MIM
131550) mutations. Although Gefitinib is one of the
most specific drugs targeting EGFR-activating mutations,
it prolongs life by only a median of 5-month progres-
sion-free survival compared with platinum-based doublet
chemotherapy.57,58 One of the reasons why current target
therapy does not work is that multiple driver mutations
shape the tumorigenic process. Combination therapy
targeting multiple driver mutations and pathways simul-
taneously has the potential to dramatically increase
survival.
In summary, we have developed a powerful and flexible
statistical framework for identifying driver genes and path-
ways in cancer genome-sequencing studies. Our statistical
approaches and several auxiliary bioinformatics tools have
been incorporated into a computational tool, DrGaP, for
cancer genomics research. This newly developed tool is
immediately applicable to cancer sequencing studies. We
believe that DrGaP provides significantly improved accu-
racy and sensitivity and can be used to identify a more
complete array of driver genes and pathways altered in
cancers.Appendix A
The LRT statistics in Equation 8 follow a mixture of
ð0:5þ εÞc20 and ð0:5 εÞc21 where ε is a positive factor,
0%ε%0:5. This correction is necessary because some
tumors have too low background mutation rate h to
observe any occurrences of a certain type of mutations in
samples. The parameter ε increases as the h decreases.er 5, 2013
To prove this fact, we start with a simple example that
considers only one single gene with one single mutation
type. Let M and N be the length of CDS that can give
rise to silent and nonsilent mutations. Suppose there
are I tumor samples with background mutation rates
hi; i ¼ 1;.; I. Denote h ¼
PI
i¼1hi. We can calculate the
probability that there are no mutations occurring across
all tumor samples under the null hypothesis (i.e., no driver
mutations):
Prðm ¼ 0; n ¼ 0 j hÞ ¼ Poissonð0; hNÞPoissonð0; hMÞ
¼ exp fhðM þNÞg:
This probability reaches nearly 1 when h become
very small. The probability of zero LRT statistics will
be larger than 0.5, because we can observe only posi-
tive discrete number of mutations f1;2; 3;.g, and no
mutations f0g across all samples that result in zero LRT
statistics.
In the above example, ε can be estimated by
ε^ ¼ Prðm ¼ 0; n ¼ 0jhÞ=2. However, in reality we should
consider all different mutation types across all different
genes for estimating. Therefore, we propose a simulation
method to estimate ε. In brief, we randomly generate
somatic mutation data under the null hypothesis.
That is, we set all of the driver mutation rates
ajk ¼ 0; j ¼ 1;.; J; k ¼ 1;.;K. We simulate the occurrence
of somatic mutations by the Poisson process with h^ij,
which is estimated by Equation 5. Then, we calculate the
LRT statistics LRTjk for each gene k ðk ¼ 1;.;KÞ and each
mutation type ðj ¼ 1;.; JÞ. The parameter ε can be
estimated by ε^ ¼ 0:5#fðj; kÞ : LRTjk > 0g=JK. Note that
the positive LRTjk  c21, we can also estimate ε by the
mean of LRTjk: ε^ ¼ 0:5
P
j
P
kLRTjk=JK.Supplemental Data
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